ArticleNeurology(R) neuroimmunology & neuroinflammation2018
VZV-associated acute retinal necrosis in a patient with MS treated with natalizumab.
Open access · goldAbstract read
In one paragraph
Article in Neurology(R) neuroimmunology & neuroinflammation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 20% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 18 citations in OpenAlex.
- Varicella-Zoster Virus and the Eye: Clinical Spectrum, Management, and Vaccination.Pathogens (Basel, Switzerland) · 2026Review
- Ten Years ofNeurology(R) neuroimmunology & neuroinflammation · 2025Article
- Reemerging Infectious Diseases and Neuroimmunologic Complications.Neurology(R) neuroimmunology & neuroinflammation · 2025Review
- Acute retinal necrosis caused by co-infection with multiple viruses in a natalizumab-treated patient: a case report and brief review of literature.BMC ophthalmology · 2021Review
- Central Nervous System Infections in Immunocompromised Patients.Current neurology and neuroscience reports · 2021Review
- Merits and culprits of immunotherapies for neurological diseases in times of COVID-19.EBioMedicine · 2020Review
- Managing Risks with Immune Therapies in Multiple Sclerosis.Drug safety · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Marc PawlitzkiDepartment of Neurology (M.P., J.T., C.C., D.B.), Otto-von-Guericke University; Department of Ophthalmology (M.W., C.S.), Otto-von-Guericke University, Magdeburg; Charité-Universitätsmedizin Berlin (F.P.), Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, NeuroCure Clinical Research Center; Department of Neurology (F.P.), Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; and Experimental and Clinical Research Center (F.P.), Max Delbrueck Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Germany.
Jan TeuberDepartment of Neurology (M.P., J.T., C.C., D.B.), Otto-von-Guericke University; Department of Ophthalmology (M.W., C.S.), Otto-von-Guericke University, Magdeburg; Charité-Universitätsmedizin Berlin (F.P.), Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, NeuroCure Clinical Research Center; Department of Neurology (F.P.), Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; and Experimental and Clinical Research Center (F.P.), Max Delbrueck Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Germany.
Christin CampeDepartment of Neurology (M.P., J.T., C.C., D.B.), Otto-von-Guericke University; Department of Ophthalmology (M.W., C.S.), Otto-von-Guericke University, Magdeburg; Charité-Universitätsmedizin Berlin (F.P.), Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, NeuroCure Clinical Research Center; Department of Neurology (F.P.), Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; and Experimental and Clinical Research Center (F.P.), Max Delbrueck Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Germany.
Markus WagnerDepartment of Neurology (M.P., J.T., C.C., D.B.), Otto-von-Guericke University; Department of Ophthalmology (M.W., C.S.), Otto-von-Guericke University, Magdeburg; Charité-Universitätsmedizin Berlin (F.P.), Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, NeuroCure Clinical Research Center; Department of Neurology (F.P.), Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; and Experimental and Clinical Research Center (F.P.), Max Delbrueck Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Germany.
Claudia SchuartDepartment of Neurology (M.P., J.T., C.C., D.B.), Otto-von-Guericke University; Department of Ophthalmology (M.W., C.S.), Otto-von-Guericke University, Magdeburg; Charité-Universitätsmedizin Berlin (F.P.), Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, NeuroCure Clinical Research Center; Department of Neurology (F.P.), Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; and Experimental and Clinical Research Center (F.P.), Max Delbrueck Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Germany.
Friedemann PaulDepartment of Neurology (M.P., J.T., C.C., D.B.), Otto-von-Guericke University; Department of Ophthalmology (M.W., C.S.), Otto-von-Guericke University, Magdeburg; Charité-Universitätsmedizin Berlin (F.P.), Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, NeuroCure Clinical Research Center; Department of Neurology (F.P.), Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; and Experimental and Clinical Research Center (F.P.), Max Delbrueck Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Germany.
Daniel BittnerDepartment of Neurology (M.P., J.T., C.C., D.B.), Otto-von-Guericke University; Department of Ophthalmology (M.W., C.S.), Otto-von-Guericke University, Magdeburg; Charité-Universitätsmedizin Berlin (F.P.), Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, NeuroCure Clinical Research Center; Department of Neurology (F.P.), Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; and Experimental and Clinical Research Center (F.P.), Max Delbrueck Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Germany.
Otto-von-Guericke University Magdeburg · DE
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.